Status:
UNKNOWN
The Role of Endothelin 1 as a Marker of Renal Impairment in Sickle Cell Disease
Lead Sponsor:
Sohag University
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
1-18 years
Brief Summary
Sickle cell disease (SCD) refers to a group of hemoglobinopathies that include mutations in the gene encoding the beta subunit of hemoglobin. Within the umbrella of SCD, many subgroups exist, namely s...
Eligibility Criteria
Inclusion
- The patients fulfilling all the following criteria will be included:
- Patients with sickle cell disease in the age range of 1-18years.
Exclusion
- Patients diagnosed to have coexistent renal disease before the study
Key Trial Info
Start Date :
October 24 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 23 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06158945
Start Date
October 24 2023
End Date
October 23 2024
Last Update
December 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sohag university Hospital
Sohag, Egypt